陳國榮


【摘要】 目的:探究麻甘顆粒聯合阿奇霉素治療小兒支原體肺炎的臨床療效。方法:選取36例2018年1月-2019年12月在筆者所在醫院治療的支原體肺炎患兒,均行麻甘顆粒聯合阿奇霉素治療,觀察本組患兒的治療效果,比較本組患兒治療前后各癥狀評分、免疫功能的變化情況及不良反應的發生率。結果:本組患者治療總有效率為94.44%(34/36),治療后各癥狀積分均低于治療前,差異有統計學意義(P<0.05);在免疫功能變化方面,治療后患者的RBC-ICR、CD8+等占比低于治療前,PBC-C3bR、CD3+、CD4+占比高于治療前,差異有統計學意義(P<0.05);本組患兒中,有1例出現肝腎功能異常,1例出現皮疹,其余患兒未出現明顯的不良反應,不良反應的發生率為5.56%(2/36)。結論:臨床上采用麻甘顆粒聯合阿奇霉素治療支原體肺炎患兒,能夠有效改善患兒的臨床癥狀,增強患兒免疫功能,療效確切,有較高的推廣價值。
【關鍵詞】 麻甘顆粒 阿奇霉素 聯合用藥 小兒支原體肺炎 免疫功能 臨床癥狀
doi:10.14033/j.cnki.cfmr.2020.15.025 文獻標識碼 B 文章編號 1674-6805(2020)15-00-03
Efficacy of Magan Granules and Azithromycin in the Treatment of Mycoplasma Pneumonia in Children/CHEN Guorong. //Chinese and Foreign Medical Research, 2020, 18(15): -60
[Abstract] Objective: To explore the clinical efficacy of Magan Granules combined with Azithromycin in the treatment of mycoplasmal pneumonia in children. Method: Thirty-six children with mycoplasma pneumonia treated in our hospital from January 2018 to December 2019 were selected, and they were all treated with Magan Granules combined with Azithromycin. The treatment effect of the children in this group was observed and compared, symptom score before and after, changes in immune function, and incidence of adverse reactions. Result: The effective rate of treatment in this group of patients was 94.44% (34/36). The symptom scores after treatment were lower than before treatment, and the difference was significant (P<0.05). In terms of changes in immune function, the proportion of RBC-ICR, CD8+ of this group of patients after treatment etc. were lower than those before treatment, and the proportion of PBC-C3bR, CD3+, and CD4+ was higher than before treatment, the difference was significant (P<0.05). One patient in this group hepatic and renal dysfunction occurred, one case developed a rash, and the other children did not have significant adverse reactions, the incidence of adverse reactions was 5.56% (2/36). Conclusion: The clinical application of Magan Granules combined with Azithromycin in the treatment of children with mycoplasma pneumonia can effectively improve the clinical symptoms of children, enhance the immune function of children, the effect is definite, and it has higher promotion value.
[Key words] Magan Granules Azithromycin Combined use of drug Mycoplasma pneumonia in children Immune function Clinical symptoms
First-authors address: Kunshan Hospital of Integrated Traditional Chinese and Western Medicine, Kunshan 215332, China
本次研究結果顯示,本組患者治療有效率為94.44%,治療后患兒各癥狀積分均低于治療前,治療后,本組患者的RBC-ICR、CD8+等占比情況低于治療前,PBC-C3bR、CD3+、CD4+占比情況高于治療前,差異有統計學意義(P<0.05)。進一步提示,麻甘顆粒聯合阿奇霉素治療支原體肺炎患兒,能夠有效改善患兒的臨床癥狀,還能達到增強機體免疫功能的作用,效果顯著。本組患兒不良反應的發生率為5.56%。說明,麻甘顆粒與阿奇霉素聯合使用治療小兒支原體肺炎患兒,并不會引發明顯的不良反應,安全性較高。
綜上所述,臨床上采用麻甘顆粒聯合阿奇霉素治療支原體肺炎患兒,能夠有效改善患兒的臨床癥狀,增強機體免疫功能,療效確切,安全性高,建議推廣在更多的臨床上。
參考文獻
[1]劉權鋒.阿奇霉素治療小兒肺炎支原體肺炎的療效及對血清相關炎癥細胞因子的影響觀察[J].首都食品與醫藥,2019,26(24):62.
[2]鄒武軍,郭煥利,李曉麗,等.麻甘顆粒聯合阿奇霉素治療小兒支原體肺炎療效研究[J].陜西中醫,2019,40(11):1582-1585,1589.
[3]梁燕錦,蔡俊欽,黃秀玲.柴桂退熱顆粒聯合阿奇霉素治療小兒支原體肺炎的療效及免疫功能分析[J].現代診斷與治療,2019,30(16):2741-2743.
[4]陳峰,孫慧明.阿奇霉素聯合小兒豉翹清熱顆粒治療支原體肺炎效果及降低炎癥細胞因子水平作用機制研究[J].山西醫藥雜志,2019,48(15):1831-1834.
[5]袁麗萍.肅肺解毒湯聯合阿奇霉素顆粒治療小兒支原體肺炎痰熱閉肺證療效觀察[J].實用中醫藥雜志,2019,35(7):830-831.
[6]王延平.雙黃連顆粒聯合阿奇霉素干混懸劑在小兒支原體肺炎治療中的應用效果[J/OL].臨床醫藥文獻電子雜志,2018,5(94):34-35.
[7]張日安,黃杏雄,陳國權.阿奇霉素聯合小兒咳喘靈顆粒治療支原體肺炎患兒的臨床效果與安全性[J].實用臨床醫學,2018,19(7):68-69.
[8]羅學錦.雙黃連顆粒與阿奇霉素干混懸劑聯合治療小兒支原體肺炎的臨床療效評價[J/OL].臨床醫藥文獻電子雜志,2017,4(33):6489-6490.
[9]任陽.阿奇霉素聯合小兒清肺顆粒治療小兒支原體肺炎的臨床療效[J].臨床合理用藥雜志,2018,11(15):70-71.
[10]王斯琦.蟬衣麻甘顆粒治療小兒急性喉支氣管炎寒熱錯雜證的臨床研究[D].濟南:山東中醫藥大學,2018.
[11]馬璇嵐,何云榮,范永存,等.小兒麻甘顆粒聯合阿奇霉素治療小兒支原體肺炎療效觀察[J/OL].中藥材,2019(12):2969-2971.
[12]宋貝,楊麗元.小兒肺咳顆粒聯合阿奇霉素治療兒童支原體肺炎的療效及對其肺功能、Th1/Th2免疫平衡的影響[J].中國婦幼保健,2019,34(24):5658-5661.
[13]雷輝,邵榮昌.玉屏風顆粒聯合痰熱清、阿奇霉素治療小兒支原體肺炎臨床觀察[J].陜西中醫,2017,38(5):631-633.
(收稿日期:2020-01-16) (本文編輯:張亮亮)